Compare WAL & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WAL | NUVL |
|---|---|---|
| Founded | 1994 | 2017 |
| Country | United States | United States |
| Employees | 3524 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.6B | 7.8B |
| IPO Year | N/A | 2021 |
| Metric | WAL | NUVL |
|---|---|---|
| Price | $70.73 | $102.43 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 16 | 16 |
| Target Price | $96.73 | ★ $134.13 |
| AVG Volume (30 Days) | ★ 1.7M | 455.9K |
| Earning Date | 04-20-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.47% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $20.25 | N/A |
| Revenue Next Year | $8.09 | $1,165.56 |
| P/E Ratio | $10.88 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $57.05 | $55.54 |
| 52 Week High | $97.23 | $113.02 |
| Indicator | WAL | NUVL |
|---|---|---|
| Relative Strength Index (RSI) | 42.21 | 57.62 |
| Support Level | $69.49 | $101.37 |
| Resistance Level | $81.14 | $107.13 |
| Average True Range (ATR) | 1.93 | 3.44 |
| MACD | 0.75 | 0.38 |
| Stochastic Oscillator | 93.72 | 90.59 |
Western Alliance Bancorp provides a full spectrum of customized loan, deposit, and treasury management capabilities, including funds transfer and other digital payment offerings. The company's reportable segments are Commercial segment includes provides commercial banking and treasury management products and services to small and middle-market businesses, specialized banking services to sophisticated commercial institutions and investors within niche industries, as well as financial services to the real estate industry. Consumer Related segment offers both commercial banking services to enterprises in consumer-related sectors and consumer banking services, such as residential mortgage banking and Corporate & Other.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of its operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.